PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.45%
R&D growth while AVXL reduces spending. John Neff would investigate strategic advantage.
69.30%
G&A growth while AVXL reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.79%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
30.79%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
1.90%
D&A growth while AVXL reduces D&A. John Neff would investigate differences.
-31.40%
EBITDA decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Operating income decline while AVXL shows 12.32% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-31.28%
Pre-tax income decline while AVXL shows 11.37% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-264.58%
Both companies reducing tax expense. Martin Whitman would check patterns.
-31.28%
Net income decline while AVXL shows 11.66% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-21.00%
EPS decline while AVXL shows 17.65% growth. Joel Greenblatt would examine position.
-22.22%
Diluted EPS decline while AVXL shows 17.65% growth. Joel Greenblatt would examine position.
7.78%
Share count reduction below 50% of AVXL's 5.28%. Michael Burry would check for concerns.
7.68%
Diluted share reduction below 50% of AVXL's 5.28%. Michael Burry would check for concerns.